miR-485-5p/NQO1 axis drives colorectal cancer progression by regulating apoptosis and aerobic glycolysis

Cancer Cell International, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 12, 2025

Language: Английский

---

Research Progress of Long Non-Coding RNA in Tumor Drug Resistance: A New Paradigm

Drug Design Development and Therapy, Journal Year: 2024, Volume and Issue: Volume 18, P. 1385 - 1398

Published: April 1, 2024

In the past few decades, chemotherapy has been one of most effective cancer treatment options. Drug resistance is currently greatest obstacles to treatment. Even though drug mechanisms have extensively investigated, they not fully elucidated. Recent genome-wide investigations revealed existence a substantial quantity long non-coding RNAs (lncRNAs) transcribed from human genome, which actively participate in numerous biological processes, such as transcription, splicing, epigenetics, cell cycle, differentiation, development, pluripotency, immune microenvironment. The abnormal expression lncRNA considered contributing factor resistance. Furthermore, may be influenced by genetic and epigenetic variations, well individual differences patient response, attributable polymorphisms metabolic enzyme genes. This review focuses on mechanism lncRNAs target drugs study tumors with high mortality, aiming establish theoretical foundation for targeted therapy.

Language: Английский

---

LINC01977 promotes colorectal cancer growth and metastasis by enhancing aerobic glycolysis via the ERK/c-Myc axis

Journal of Gastrointestinal Oncology, Journal Year: 2024, Volume and Issue: 15(1), P. 271 - 285

Published: Feb. 1, 2024

Background: How colorectal cancer (CRC) gain the ability to growth and metastasis remains largely unknown. Findings from preceding studies have revealed participation of long non-coding RNAs (lncRNAs) in CRC progression. However, role LINC01977 unexplored. This study aims explore function underlying mechanism CRC. Methods: The Cancer Genome Atlas (TCGA) Gene Expression Omnibus (GEO) datasets were used analyze expression its correlation with prognosis. In our research, we explored influence on progression such as cell proliferation, migration, invasion, aerobic glycolysis, identified fundamental molecular using vitro lines vivo mouse xenograft models. Results: exhibited significantly elevated tissues lines, level was correlated malignant clinicopathological characteristics negative Furthermore, both tests LINC01977's facilitating proliferation metastasis. significant part glycolysis also discovered. With an aim uncover mechanism, investigated effect c-Myc, a key gene glycolysis. results showed that regulated c-Myc stability via extracellular signal-regulated kinase (ERK)-mediated phosphorylation, LINC01977-mediated activated vital glycolysis-related genes HK2, PGK1, LDHA, GLUT1. Rescue experiments further confirmed promoted metastasis, c-Myc. Conclusions: is first report facilitates through suggesting potential therapeutic target for treatment.

Language: Английский

---

Metabolic Reprogramming in Prostate Cancer: The Roles of HOXB13 and FASN in Tumor Progression and Therapy

Published: Jan. 14, 2025

Metabolic reprogramming, particularly lipid metabolism, is a hallmark of cancer progression and critical vulnerability in prostate (PCa). Two pivotal studies, one by Lu et al. the other Dairo al., have illuminated roles HOXB13, transcriptional regulator, fatty acid synthase (FASN), key enzyme biosynthesis, metabolic dysregulation PCa. The study highlights HOXB13’s role androgen receptor (AR)-independent PCa, where it regulates metabolism via epigenetic mechanisms involving histone deacetylase HDAC3. A G84E mutation HOXB13 disrupts this regulation, leading to increased synthesis pro-metastatic phenotype. demonstrates that FASN hypomethylation, coupled with expression, drives biosynthesis for tumor growth. Both studies establish link between mutations dysregulation, underscoring their interplay PCa biology. Therapeutically, pharmacological inhibition mitigates aggressive features HOXB13-deficient or mutant highlighting as promising target. Despite strengths, including robust methodologies, limitations include reliance on preclinical models need broader patient diversity. These collectively emphasize potential interventions precision medicine paving way novel therapies targeting patients specific genetic profiles.

Language: Английский

---

Sanqi oral solution ameliorates renal fibrosis by suppressing fibroblast activation via HIF-1α/PKM2/glycolysis pathway in chronic kidney disease

Journal of Ethnopharmacology, Journal Year: 2024, Volume and Issue: 335, P. 118679 - 118679

Published: Aug. 8, 2024

Sanqi oral solution (SQ) is a traditional Chinese patent medicine, widely used to treat chronic kidney diseases (CKD) in the clinic China. Previous studies have confirmed its anti-renal fibrosis effect, but specific pharmacological mechanism still unclear.

Language: Английский

---

Targeted therapies and precision medicine in colorectal cancer drug resistance

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 65 - 82

Published: Nov. 8, 2024

Language: Английский

---

Hesperidin Suppressed Colorectal Cancer through Inhibition of Glycolysis

Chinese Journal of Integrative Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 25, 2024

Language: Английский

---

The ratio of PKM1/PKM2 is the key factor affecting the glucose metabolism and biological function of colorectal cancer cells

Translational Cancer Research, Journal Year: 2024, Volume and Issue: 13(7), P. 3522 - 3535

Published: July 1, 2024

Despite evidence suggesting a significant role of pyruvate kinase muscle isozyme (PKM) in cancer development, its particular function colorectal (CRC) remains unclear. This study aimed to elucidate the specific and mechanism PKM isoforms, PKM1 PKM2, progression CRC.

Language: Английский

---